The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS

Gut

Volumn 66, Issue 8, 2017, Pages 1403-1413

  Tack, J ^a   Schumacher, K ^b   Tonini, G ^c   Scartoni, S ^c   Capriati, A ^c   Maggi, C A ^c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Menarini Research and Business Service GmbH   (Germany)

^c Menarini Ricerche SpA   (Italy)

Author keywords

CLINICAL TRIALS; IRRITABLE BOWEL SYNDROME; MOTILITY DISORDERS; NEUROGASTROENTEROLOGY; VISCERAL SENSITIVITY

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; IBODUTANT; NEUROKININ 1 RECEPTOR ANTAGONIST; PLACEBO; DIPEPTIDE; GASTROINTESTINAL AGENT; NEUROKININ 2 RECEPTOR; THIOPHENE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; APPENDICITIS; ARTICLE; CONTROLLED STUDY; DIARRHEA PREDOMINANT IRRITABLE BOWEL SYNDROME; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FECES; FEMALE; GASTROENTERITIS; HEADACHE; HUMAN; INFLUENZA; IRRITABLE COLON; MAJOR CLINICAL STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RHINOPHARYNGITIS; SYMPTOM; UPPER RESPIRATORY TRACT INFECTION; ADOLESCENT; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; COMPLICATION; DIARRHEA; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SEX FACTOR; SYMPTOM ASSESSMENT; YOUNG ADULT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; DIARRHEA; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IRRITABLE BOWEL SYNDROME; MALE; MIDDLE AGED; QUALITY OF LIFE; RECEPTORS, NEUROKININ-2; SEX FACTORS; SYMPTOM ASSESSMENT; THIOPHENES; YOUNG ADULT;

EID: 84964669971     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-310683     Document Type: Article

References (38)

1. Drossman DA, Corazziari E, Delvaux M, et al. Rome III. The functional gastrointestinal disorders. 3rd edn. Degnon Associates, 2006.
2. Andrews EB, Eaton SC, Hollis KA, et al. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther 2005;22:935-42.
3. Cremonini F, Talley NJ. Talley, Irritable bowel syndrome: epidemiology, natural history, health care seeking and emerging risk factors. Gastroenterol Clin North Am 2005;34:189-204.
4. Boyce PM, Talley NJ, Burke C, et al. Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: An Australian population-based study. Intern Med J 2006;36:28-36.
5. Spiller R, Aziz Q, Creed F, et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 2007;56:1770-98.
6. Longstreth GF, Thompson WG, Chey WD, et al. Functiona bowel disorders. Gastroenterology 2006;130:1480-91.
7. Rpiller RC, Thompson WG. Bowel disorders. Am J Gastroenterol 2010;105:775-85.
8. Ford AC, Talley NJ, Spiegel BM, et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-Analysis. BMJ 2008;337:a2313.
9. Ford AC, Brandt LJ, Young C, et al. Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-Analysis. Am J Gastroenterol 2009;104:1831-43; quiz 1844.
10. Vanuytsel T, Tack JF, Boeckxstaens GE. Treatment of abdominal pain in irritable bowel syndrome. J Gastroenterol 2014;49:1193-205.
11. Altamura M. Tachykinin NK2 receptor antagonists. A patent review (2006-2010). Expert Opin Ther Pat 2012;22:57-77.
12. Quartara L, Altamura M, Evangelista S, et al. Tachykinin receptor antagonists in clinical trials. Expert Opin Investig Drugs 2009;18:1843-64.
13. dos Santos LV, Souza FH, Brunetto AT, et al. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: A systematic review. J Natl Cancer Inst 2012;104:1280-92.
14. Hargreaves R, Ferreira JC, Hughes D, et al. Development of aprepitant, the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting. Ann N Y Acad Sci 2011;1222:40-8.
15. Jaafari N, Khomitch-Baud A, Christen MO, et al. Distribution pattern of tachykinin NK2 receptors in human colon: involvement in the regulation of intestinal motility. J Comp Neurol 2007;503:381-91.
16. Shimizu Y, Matsuyama H, Shiina T, et al. Tachykinins and their functions in the gastrointestinal tract. Cell Mol Life Sci 2008;65:295-311.
17. Giuliani S, Barbanti G, Turini D, et al. NK2 tachykinin receptors and contraction of circular muscle of the human colon: characterization of the NK2 receptor subtype. Eur J Pharmacol 1991;203:365-70.
18. Maggi CA, Patacchini R, Santicioli P, et al. Human isolated ileum: motor responses of the circular muscle to electrical field stimulation and exogenous neuropeptides. Naunyn Schmiedebergs Arch Pharmacol 1990;341:256-61.
19. Laird JM, Olivar T, Lopez-Garcia JA, et al. Responses of rat spinal neurons to distension of inflamed colon: role of tachykinin NK2 receptors. Neuropharmacology 2001;40:696-701.
20. Sculptoreanu A, Aura Kullmann F, de Groat WC. Neurokinin 2 receptor-mediated activation of protein kinase C modulates capsaicin responses in DRG neurons from adult rats. Eur J Neurosci 2008;27:3171-81.
21. Toulouse M, Coelho AM, Fioramonti J, et al. Role of tachykinin NK2 receptors in normal and altered rectal sensitivity in rats. Br J Pharmacol 2000;129:193-9.
22. Lecci A, Altamura M, Capriati A, et al. Tachykinin receptors and gastrointestinal motility: focus on humans. Eur Rev Med Pharmacol Sci 2008;12(Suppl 1):69-80.
23. Lecci A, Capriati A, Altamura M, et al. Tachykinins and tachykinin receptors in the gut, with special reference to NK2 receptors in human. Auton Neurosci 2006;126-127:232-49.
24. Corsetti M, Akyuz F, Tack J. Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome. Neurogastroenterol Motil 2015;27:1354-70.
25. Lördal M, Navalesi G, Theodorsson E, et al. A novel tachykinin NK2 receptor antagonist prevents motility-stimulating effects of neurokinin A in small intestine. Br J Pharmacol 2001;134:215-23.
26. Corsetti M, Akyuz F, Tack J. Targeting tachykinin receptors for the treatment of functional gastrointestinal disorders with a focus on irritable bowel syndrome. Neurogastorenteorl Motil 2015;27:1354-70.
27. Cialdai C, Tramontana M, Patacchini R, et al. MEN15596, a novel nonpeptide tachykinin NK2 receptor antagonist. Eur J Pharmacol 2006;549:140-8.
28. Points to consider on the evaluation of medicinal products for the treatment of irritable bowel syndrome. CPMP/EWP/785/97, London 19 March 2003.
29. Guidance for Industry-Irritable Bowel Syndrome-Clinical evaluation of drugs for treatment; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). May 2012.
30. Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997;32:920-4.
31. Tack J, Fried M, Houghton LA, et al. Systematic review: The efficacy of treatments for irritable bowel syndrome-A European perspective. Aliment Pharmacol Ther 2006;24:183-205.
32. Chang L, Chey WD, Harris L, et al. Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data. Am J Gastroenterol 2006;101:1069-79.
33. Cash BD, Lacy BE, Rao T, et al. Rifaximin and eluxadoline-newly approved treatments for diarrhea-predominant irritable bowel syndrome: what is their role in clinical practice alongside alosetron? Expert Opin Pharmacother 2015:17:311-22.
34. Schoenfeld P, Talley NJ. Measuring successful treatment of irritable bowel syndrome: is "satisfactory relief " enough? Am J Gastroenterol 2006;101:1066-8.
35. Camilleri M, Mangel AW, Fehnel SE, et al. Primary endpoints for irritable bowel syndrome trials: A review of performance of endpoints. Clin Gastroenterol Hepatol 2007;5:534-40.
36. Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil 2013;25:453-7.
37. Wolf-Johnston AS, Kullmann FA, Beckel JM, et al. Effect of ibodutant, a neurokinin NK2 receptor antagonist, on gender-related influences following induction of trinitrobenzenesulfonic acid-induced colitis in the Guinea Pig. Gastroenterology 148: S-777 (abstract).
38. Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: A disease-specific quality-of-life questionnaire. Am J Gastroenterol 2000;95:999-1007.